Sponsors (76)
Introduced June 4, 2025 by Frank Pallone · Last progress June 4, 2025
The bill strengthens and speeds access to ACIP-recommended vaccines and increases transparency and funding for advisory operations, but it reduces HHS discretion, introduces tight review deadlines and reporting that could politicize or rush scientific decisions, and may slow changes to the Vaccine Injury Table with modest additional federal cost.
Children, Medicaid beneficiaries, and insured patients will have clearer, more consistent access to ACIP-recommended pediatric vaccines because the bill creates a statutory VFC vaccine list and requires group/individual health plans to cover ACIP-recommended immunizations without cost‑sharing.
The bill speeds the pathway for new licensed vaccines to receive official recommendations (90‑day review targets and earlier meetings) so patients can access new vaccines faster.
Provides predictable annual funding for ACIP operations (authorized $2.8M/year FY2026–2029), helping maintain committee capacity to review vaccines and produce timely recommendations.
HHS is generally required to adopt ACIP recommendations unless it publishes a scientific rationale for not doing so, which reduces the Secretary's flexibility and could hamper fast, tailored responses in emergencies or complex policy situations.
Tight statutory deadlines for reviews (e.g., 90 days) and faster timelines overall may pressure ACIP and manufacturers, raising the risk of rushed or incomplete evidence synthesis for complex vaccines and potentially compromising safety or recommendation quality.
Mandatory rapid public reporting and congressional notifications when recommendations aren't adopted (within 48 hours) could politicize scientific decisionmaking and subject experts to immediate political pressure.
Based on analysis of 3 sections of legislative text.
Codifies ACIP in statute, requires HHS to accept its vaccine recommendations unless contradicted by a preponderance of peer‑reviewed evidence, and raises the evidence bar for Vaccine Injury Table changes.
Makes the federal vaccine advisory committee (ACIP) a statutory advisory body and requires HHS to accept its evidence-based vaccine recommendations for use in the civilian population unless the Secretary or Director publishes a reasoned finding showing the recommendation is not supported by a preponderance of the best available, peer‑reviewed scientific evidence. It also requires rapid internal and congressional notifications when the Department departs from ACIP guidance and sets deadlines for the Committee to review newly licensed vaccines and certain emergency or breakthrough-designated products. Separately, it raises the evidentiary standard for removing or changing vaccines or listed injuries on the Vaccine Injury Table, requiring such changes be supported by a preponderance of the best available scientific evidence.